SOPHSophia Genetics SA
About Sophia Genetics SA
Sophia Genetics (NASDAQ:SOPH) specializes in data-driven medicine, focusing on the development and use of advanced computational techniques to support healthcare professionals in diagnosing and treating diseases. It operates globally, leveraging artificial intelligence to analyze clinical and genomic data with the aim to improve disease detection, treatment, and overall patient outcomes. Their projects range from cancer research to rare diseases, striving to break new ground in personalized medicine and collaborative healthcare networks. With a mission to make clinical genomics more accessible and actionable, Sophia Genetics is committed to transforming healthcare through data intelligence and contributing to a more sustainable global health ecosystem.
What is SOPH known for?
Snapshot
Public US
Ownership
2011
Year founded
430
Employees
Lausanne, Switzerland
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Switzerland
Produtos e/ou serviços de Sophia Genetics SA
- Sophia DDM platform utilizes AI for genomic analysis, offering insights into complex diseases like cancer.
- Liquid biopsy solutions for non-invasive cancer detection and monitoring through blood samples.
- Hereditary cancer testing to identify genetic predispositions to various cancers, enhancing personalized treatment planning.
- Genomic data storage and security services that ensure the integrity and confidentiality of sensitive genetic information.
- Collaborative data-sharing platform that enables researchers and clinicians to exchange genomic and phenotypic data, advancing personalized medicine.
- AI-driven analytics for clinical trials, optimizing patient selection and enhancing drug development processes.
equipe executiva do Sophia Genetics SA
- Dr. Jurgi Camblong M.B.A., Ph.D.Co-Founder, CEO & Director
- Mr. Ross Jordan Muken B.Sc.President
- Mr. George A. Cardoza M.B.A.Executive VP & CFO
- Mr. Abhimanyu VermaEVP & Chief Technology Officer
- Dr. Zhenyu Xu Ph.D.Executive VP & Chief Scientific Officer
- Kellen SangerHead of Strategy and Investor Relations
- Mr. Daan van Well L.L.M., M.B.A.Executive VP, Chief Legal & Regulatory Officer
- Mr. Kevin PuylaertSVP & Chief Sales Officer
- Ms. Manuela Da Silva Valente B.A.Executive VP & Chief People Officer
- Dr. Philippe Menu M.B.A., M.D., Ph.D.Executive VP, Chief Medical Officer & Chief Product Officer